









Markets
/
Stocks
/
nasdaq-cing
/

Cingulate Inc

CING

View Detailed Chart

5.100USD

-0.080-1.54%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

19.51MMarket Cap

LossP/E TTM



Cingulate Inc

5.100

-0.080-1.54%

Overview Company Financials

Financials

Intraday

30m

Today

-1.54%

5 Days

-7.27%

1 Month

+19.16%

6 Months

+12.83%

Year to Date

+3.45%

1 Year

+36.57%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

29.000

Target Price

468.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Cingulate Inc

CING

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(4)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.055

Neutral

RSI(14)

55.445

Neutral

STOCH(KDJ)(9,3,3)

30.189

Sell

ATR(14)

0.382

High Vlolatility

CCI(14)

-45.194

Neutral

Williams %R

56.875

Sell

TRIX(12,20)

0.979

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.170

Sell

MA10

5.368

Sell

MA20

4.994

Buy

MA50

4.485

Buy

MA100

4.247

Buy

MA200

4.326

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Ticker SymbolCING

CompanyCingulate Inc

CEODr. Shane J. Schaffer, Pharm.D.

Websitehttps://www.cingulate.com/